Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 6/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 4/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.47 |
| ▸ | PLG | P00747 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21496636 | 0.80 | TACR1 (0.51) | CYP2C9CYP2D6SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL2435076 | 0.76 | TACR1 (0.48) | TSHRALDH1A1MAPK1GRM5CYP2C19 | |
| SCHEMBL20493405 | 0.74 | TACR1 (0.42) | CYP2D6SMN1; SMN2TSHRALDH1A1MAPK1 | |
| SCHEMBL20493402 | 0.74 | TACR1 (0.42) | CYP2D6SMN1; SMN2TSHRALDH1A1MAPK1 | |
| SCHEMBL8000886 | 0.74 | TSHR (0.48) | CYP2C9CYP2D6SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL15105750 | 0.73 | TACR1 (0.46) | TSHRALDH1A1MAPK1GRM5 | |
| SCHEMBL27953255 | 0.73 | TACR1 (0.64) | — | |
| SCHEMBL1446835 | 0.73 | TACR1 (0.60) | SMN1; SMN2TSHR | |
| SCHEMBL6187228 | 0.73 | ITGB3 (0.51) | SMN1; SMN2ALDH1A1MAPK1F10ITGB3 | |
| SCHEMBL19839312 | 0.71 | HTR2C (0.44) | CYP2C9SMN1; SMN2TSHRALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172416-A1 | AMIDINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2311810-A1 | AMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172416-A1 | AMIDINE DERIVATIVE | SERPINC1, F12, F11 | CYP2C9 847/4885CYP2D6 3080/4885HIF1A 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.